Persistence and antiviral resistance of varicella zoster virus in hematological patients

Clinical Infectious Diseases

Volumn 56, Issue 3, 2013, Pages 335-343

  Van Der Beek, Martha T ^a   Vermont, Clementien L ^a   Bredius, Robbert G M ^a   Marijt, Erik W A ^a   Van Der Blij De Brouwer, Caroline S ^a   Kroes, Aloys C M ^a   Claas, Eric C J ^a   Vossen, Ann C T M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antiviral resistance; hematological patients; HSCT; persistence; VZV

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; THYMIDINE KINASE; VALACICLOVIR; VIRUS DNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ARTICLE; CHEMOPROPHYLAXIS; CHILD; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEWBORN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINITIS; SEQUENCE ANALYSIS; VARICELLA ZOSTER VIRUS; VIRUS ENCEPHALITIS; VIRUS GENE; VIRUS LOAD;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BLOOD; CHILD; COMBINED MODALITY THERAPY; DRUG RESISTANCE, VIRAL; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION; YOUNG ADULT;

EID: 84872334436     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis879     Document Type: Article

References (38)

1. Shiley K, Blumberg E. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Infect Dis Clin North Am 2010; 24:373-93.
2. Kim DH, Messner H, Minden M, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10:90-8.
3. Leung TF, Chik KW, Li CK, et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 25:167-72.
4. Onozawa M, Hashino S, Haseyama Y, et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant 2009; 15:724-9.
5. Peritz DC, Duncan C, Kurek K, Perez-Atayde AR, Lehmann LE. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versushost disease (cGVHD). J Pediatr Hematol Oncol 2008; 30:931-4.
6. Vandenbosch K, Ovetchkine P, Champagne MA, Haddad E, Alexandrov L, Duval M. Varicella-zoster virus disease is more frequent after cord blood than after bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14:867-71.
7. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 (suppl 1):S2-S7.
8. Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365-76.
9. Kalpoe JS, Kroes AC, Verkerk S, Claas EC, Barge RM, Beersma MF. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation. Bone Marrow Transplant 2006; 38:41-6.
10. Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes 2007; 14:32-6.
11. Distler E, Schnurer E, Wagner E, et al. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol Blood Marrow Transplant 2008; 14:1417-24.
12. Onozawa M, Hashino S, Takahata M, et al. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients. J Clin Microbiol 2006; 44:4441-3.
13. van der Heiden PL, de BR, van der Steen DM, et al. Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation. J Virol 2009; 83:7361-4.
14. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170:68-75.
15. Brink AA, van GM, Wolffs PF, Bruggeman CA, van Loo IH. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis 2011; 52:982-7.
16. Hatchette T, Tipples GA, Peters G, Alsuwaidi A, Zhou J, Mailman TL. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008; 27:75-7.
17. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999; 43:2412-6.
18. Saint-Leger E, Caumes E, Breton G, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 33:2061-7.
19. Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 2011; 90:242-7.
20. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993; 67:1024-33.
21. Cole NL, Balfour HH Jr. Varicella-zoster virus does not become more resistant to acyclovir during therapy. J Infect Dis 1986; 153:605-8.
22. Ozaki T, Nishimura N, Kajita Y, Ida M, Shiraki K. Susceptibilities to aciclovir in viral isolates from children with varicella. Arch Dis Child 1998; 78:95.
23. van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003; 41:576-80.
24. Andrei G, Topalis D, Fiten P, et al. In vitro-selected drug-resistant varicella- zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 2012; 86:2641-52.
25. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5:88-114.
26. Bleymehl K, Cinatl J, Schmidt-Chanasit J. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet. Med Microbiol Immunol 2011; 200:193-202.
27. Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 1999; 59:84-90.
28. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6:44-9.
29. Ferreira M, Sanches M, Teixeira M, Guerra M, Selores M. Persistent varicella as the initial manifestation of systemic lymphoma. Dermatol Online J 2008; 14:24.
30. Mahalingam R, Wellish M, Brucklier J, Gilden DH. Persistence of varicella- zoster virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol 1995; 1:130-3.
31. Quinlivan ML, Ayres KL, Kelly PJ, et al. Persistence of varicella-zoster virus viraemia in patients with herpes zoster. J Clin Virol 2011; 50:130-5.
32. Cohen JI, Straus SE, Arvin AM. Varicella-zoster virus replication, pathogenesis and management. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2011:2773-818.
33. Morfin F, Frobert E, Thouvenot D. Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus. Ann Biol Clin (Paris) 2003; 61:33-40.
34. Sahli R, Andrei G, Estrade C, Snoeck R, Meylan PR. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame. Antimicrob Agents Chemother 2000; 44:873-8.
35. Boom R, Sol CJ, Schuurman T, et al. Human cytomegalovirus DNA in lasma and serum specimens of renal transplant recipients is highly fragmented. J Clin Microbiol 2002; 40:4105-13.
36. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110:3071-7.
37. Klein A, Miller KB, Sprague K, DesJardin JA, Snydman DR. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplant 2011; 46:294-9.
38. Oshima K, Takahashi T, Mori T, et al. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 2010; 12:421-7.